Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Masashi Takemoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nagoya City University Midori Municipal Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Anthracyclines, Neoplasm Recurrence, Local. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Background
Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.
Methods
This study included elderly patients (aged ≥70 years) with refractory, relapsed SCLC who received amrubicin monotherapy at Nagoya City University Hospital between April 2009 and March 2023. Patients were divided into two groups based on the initial dose: the low-dose group (<40 mg/m2) and the high-dose group (≥40 mg/m2).
Results
Forty-seven patients were included, thirty-eight in the low-dose group and nine in the high-dose group. Median progression-free survival was significantly longer in the low-dose group than in the high-dose group (3.64 vs. 1.5 months, P = 0.04), whereas overall survival was not significantly different (10.18 vs. 8.18 months, P = 0.58). Febrile neutropenia occurred in seven patients. Treatment discontinuation due to adverse events was more frequent in the high-dose group (44.4%) than in the low-dose group (13.5%). Non-infectious adverse events such as interstitial pneumonia, arrhythmia, and myocardial infarction were observed in five patients who discontinued treatment.
Conclusions
Both hematological and non-infectious adverse events may have contributed to shorter progression-free survival in the high-dose group. Low-dose administration, granulocyte colony-stimulating factor support, and close monitoring for non-infectious toxicities may be important in elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nagoya City University Midori Municipal Hospital, Nagoya, Japan.
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Respiratory Medicine, Chita Kosei Hospital, Chita district, Japan.
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
ORCID-Profile: Masashi Takemoto, Shiori Kinoshita
Zitieren
APA
Takemoto, M., Kinoshita, S., Yamada, K., Asaoka, M., Hotta, Y., Furukawa-Hibi, Y., Uemura, T., & Komatsu, H. (2025). Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf140
Vancouver
Takemoto M, Kinoshita S, Yamada K, Asaoka M, Hotta Y, Furukawa-Hibi Y, et al. Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf140
BibTeX
@article{Takemoto2025,
author = {Takemoto, Masashi and Kinoshita, Shiori and Yamada, Kazuki and Asaoka, Minami and Hotta, Yuji and Furukawa-Hibi, Yoko and Uemura, Takehiro and Komatsu, Hirokazu},
title = {Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf140}
}
EUVIMED